Skip to main content

Table 2 Meta-analysis results for variants analysed on OncoArray only in the unadjusted analyses in Table 1

From: Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

Subgroup

Variant

Chr

Position

Allelesa

AAF

Unadjusted meta-analysis

Adjusted meta-analysis

HR [95% CI]

P value

BFDP

HR [95% CI]

P value

BFDP

Grade 3 tumors

rs5934618

X

9437463

A/G

0.08

1.32 [1.20,1.45]

1.4E-08

0.01

1.31 [1.18, 1.44]b

7.9E-08

0.05

rs4830644

9434808

A/G

0.08

1.32 [1.20,1.45]

2.1E-08

0.01

1.30 [1.18, 1.43]b

1.7E-07

0.10

rs3810742

9432603

T/C

0.08

1.31 [1.19,1.44]

2.7E-08

0.02

1.29 [1.17, 1.42]b

1.8E-07

0.10

rs4830642

9431786

T/C

0.08

1.31 [1.19,1.44]

2.8E-08

0.02

1.29 [1.17, 1.42]b

2.2E-07

0.12

rs72611496

9434264

G/A

0.08

1.32 [1.20,1.45]

2.3E-08

0.02

1.30 [1.18, 1.43]b

2.5E-07

0.13

ER+ or PR+, and HER2- not treated with CT

rs56248395

11

20084391

C/T

0.13

1.53 [1.25,1.89]

5.2E-05

0.97

1.52 [1.24,1.87]c

6.4E-05

0.98

  1. Abbreviations: Chr chromosome, AAF alternative allele frequency, HR hazard ratio, CI confidence interval, BFDP Bayesian False Discovery Probability
  2. Note: BFDP is computed assuming the prior probability of true association equal to 10-4 for all variants, which implies a number of expected true associations in the order of 102. Results with BFDP<0.15 in the adjusted analyses are bolded. aReference/Alternative alleles, bAdjusted for age at diagnosis, lymph node status, tumor size, distant metastases status, ER status, HER2 status, (neo)adjuvant CT, cAdjusted for age at diagnosis, lymph node status, tumor size, and tumor grade
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us